Our organization

Board, committees and an organigram. How we are organized and who does what: learn more about us.

Oncode Institute operates with a small team to provide valorization services, general management and support to all the Oncode Researchers across the Partner Institutions. Oncode does not have its own research facilities or staff. Every Oncode Researcher is employed by one of the Partner Institutions, at which the actual research is conducted.

Oncode’s staff is guided and supported by its board and committees. The Oncode team and the members of the boards and committees perform their duties in awareness of their extraordinary responsibility to spend public monies in the most effective and efficient manner possible, to serve society and to set an example.

Oncode is founded on the assumption that everyone involved in the Institute is committed to constantly improving Oncode and its way of working. Oncode listens. Not only to its boards, committees and the Oncode team, but to all Oncode Researchers, partners and patients. Because all of us together know more than the few managing the Institute. If you have any questions or suggestions, please feel free to contact us at any time.

Oncode organization chart

Managing Board

The members of the Managing Board operate and manage Oncode, taking into account that Oncode has an important social responsibility. The Managing Board consists of the Head of the Institute, Managing Director and a Valorization Director.

Geert Kops Head of the Institute

Oncode Investigator Geert Kops is the Head of the Institute and chair of the Research Management Committee of Oncode Institute. Geert Kops is group leader at the Hubrecht Institute and professor of Molecular Tumor Cell Biology at the University Medical Center Utrecht. His group studies the signaling networks that regulate chromosome segregation, the evolution of cell division processes and the role of chromosomal instability in cancer.

"Synergy between Oncode researchers will create even more breakthrough discoveries, also towards the clinic.”

Alain Kummer Managing Director
Chris De Jonghe Valorization Director
Research Management Committee
Geert Kops Hubrecht Institute (Chair)
Jan Paul Medema AMC
Karin de Visser NKI
Madelon Maurice UMC Utrecht
Ruud Delwel Erasmus MC
Thijn Brummelkamp NKI
Mario van der Stelt Leiden University
Henk Verheul Radboud UMC (Chair CAB)
Clinical Advisory Board
Henk Verheul Radboud UMC (Chair CAB)
Marleen Kok Antoni van Leeuwenhoek
Natasha van Eijkelenburg Princess Máxima Institute
Ritse Mann Radboud UMC
Joop Kroes Patient Representative
Ewout Steyerberg LUMC
Ferry Eskens Erasmus MC
Mette Hazenberg Amsterdam UMC, Location AMC
Jeanine Roodhart UMC Utrecht
Muriëlle Sark Patient Representative
Lianne Bogers Patient Representative
Supervisory Board
Eduard Klasen

Eduard Klasen

Chair

Eduard Klasen has served in many leaderships roles during his extensive career. After ten years as member of the Executive Board of Leiden University Medical Center, he currently is an advisor to the Board. In 2012 he was knighted by Her Majesty the Queen of the Netherlands. Eduard is member of the Supervisory Board of VU, Free University Amsterdam, chairman of the Supervisory Board of the Wilhelmina Hospital Assen, chairman of the Supervisory Board of NIVEL, advisor to the UMCG, University Medical Center Groningen, among various other supervisory positions.


Chair
Ben Feringa

Ben Feringa

Supervisory Board

Ben Feringa is Jacobus van ‘t Hoff Distinguished Professor of Molecular Sciences at the University of Groningen. His research interest includes stereochemistry, organic synthesis, asymmetric catalysis, molecular switches and motors, self-assembly, molecular nanosystems and photopharmacology. He received the 2016 Nobel Prize in chemistry and was knighted by Her Majesty the Queen of the Netherlands in 2008. He is Board Member of the Royal Netherlands Academy of Sciences (KNAW), Chairman Board Chemistry Division of the Netherlands Science Foundation NWOCW among many other involvements.

Get In Touch:


Supervisory Board
Edvard Beem

Edvard Beem

Supervisory Board

Until 2017, Edvard Beem has served as co-director of The Netherlands Organisation for Health Research and Development (ZonMw). Since its establishment in 2001, he was responsible for research strategy, public-private co-operation and international relations at ZonMw. Edvard was originally trained as a biochemist and spend most of his scientific career at the Netherlands Cancer Institute. He also serves as the chair of the General Assembly of Joint Programming Initiative “More Years, Better Lives” and held governmental positions in numerous international funding consortia promoting European and global collaboration in research, innovation and infrastructures.


Supervisory Board
Erica van Wuijtswinkel

Erica van Wuijtswinkel

Supervisory Board

Erica van Wuijtswinkel is the patient representative within the Oncode Supervisory Board. She is also a member of the patient advisory board at the Dutch Cancer Society (KWF). In her professional career she has dealt with navigating through subsidy opportunities in several different projects. Here Erica has also learned to take a holistic and multi-stakeholder approach to projects and to see the bigger picture as opposed to focusing on one side of the coin only. During her career she developed a talent for implementing policy, promoting cooperation within and between organizations and combining technology, support & care.

Get In Touch:


Supervisory Board
Johan van de Gronden

Johan van de Gronden

Supervisory Board

Johan van de Gronden is executive director of the Dutch Cancer Society. His career spans senior management and leadership roles across civil society, government and business. He was the CEO of the World Wide Fund for Nature (WWF) in the Netherlands for a decade, served the international community at the United Nations Development Programme (UNDP) and the Dutch Foreign Office. He now chairs the boards of the International Union for Conservation of Nature (IUCN), the Early Music Foundation and the Amazon Conservation Team in Brussels.


Supervisory Board
René Kuijten

René Kuijten

Supervisory Board

René Kuijten is one of the initiators of Oncode Institute and is managing partner at the international healthcare investment firm Life Sciences Partners (LSP). After his training as a physician in Utrecht he obtained a PhD degree as a WHO fellow, based on cancer research performed at the University of Pennsylvania. He received his MBA from INSEAD and was a consultant at McKinsey & Co. in Amsterdam, Zurich and Brussels from 1992-2000, a.o. leading their healthcare practice. In 2001 he joined LSP and has founded and supported many life science companies. René also serves as a member of the steering committee in the Dutch Topsector Life Science & Health and is in the management board of the Dutch private equity and venture capital association (NVP).


Supervisory Board
Tanja Nagel

Tanja Nagel

Supervisory Board

Tanja Nagel has had a long career in the financial sector. In 2009 she became CEO at Theodoor Gillissen Bankers, a position she held until 2017. During her career she has gained ample experience in supervising diverse organisations and companies. Amongst others, she served on the supervisory boards of the Pink Ribbon Foundation and The National Maritime Museum and chaired the audit committee in both boards. Next to her role at Oncode, she currently serves in in the board of the Utrecht University Fund and in the supervisory boards of PNO consultants and EY The Netherlands.


Supervisory Board
Hans Van Leeuwen

Hans Van Leeuwen

Supervisory Board

Hans (J.P.T.M.) van Leeuwen studied biology at the Free University in Amsterdam with focus on Endocrinology. He did his PhD study at Leiden University, Leiden. He was recruited by the department of Internal Medicine of Erasmus University Medical Center (Erasmus MC) to develop a research program on skeletal and calcium- and phosphate-related disorders. He initiated the research program on the genetics of osteoporosis. He is professor of Calcium and Bone Metabolism. His focus area is regenerative medicine, control of mesenchymal stem cell and osteoblast differentiation and its impact on bone metabolism with ageing, on hematopoietic stem cell control and on cancer cell metastasis. He founded a biotech start-up to develop therapies to stimulate bone formation and enhance bone strength. He was member of the executive boards of the European Society for Calcified Tissues, The Advances in Mineral Metabolism and is currently secretary/treasurer of the American Society for Bone and Mineral Research. He has organized numerous national and international scientific workshops and congresses. Currently he is Dean of the faculty of Medicine and Health Sciences and vice-chair of the Erasmus MC Executive Board.

Get In Touch:


Supervisory Board
International Advisory Board
David Livingston Dana-Farber Institute (Chair)
Karen Vousden Francis Crick Institute
Laura van 't Veer UCSF Helen Diller Family Comprehensive Cancer Center
Richard Marais Paterson Institute and CRUK
Stan Kaye The Institute of Cancer Research
Teri Willey Vice President for Business Development & Technology Transfer - ‎Cold Spring Harbor Laboratory
Vishva Dixit Genentech
Clare Isacke

Clare Isacke

ICR London

Professor Clare Isacke studied Biochemistry and graduatedin Developmental Biology with John Heath at the University of Oxford. She then moved to Tony Hunter's laboratory at the Salk Institute in San Diego to work on growth factor receptor signalling as a postdoctoral fellow. On returning to England, she started her own research laboratory first in the Department of Biochemistry and then in the Department of Biology at Imperial College London. She was appointed Professor of Molecular Cell Biology in 2000. In 2001, Professor Isacke moved to The Institute of Cancer Research in London to take up an appointment as Professor of Molecular Cell Biology in the Breast Cancer Now Toby Robins Research Centre. Currently, she is Academic Dean at the ICR. Professor Isacke aims to identify the processes by which tumour cells recruit non-cancerous cells during metastasis.

Get In Touch:


ICR London
Drug Repurposing Advisory Board
Mario van der Stelt Leiden University
Roderick Beijersbergen NKI
Jannie Borst LUMC
Paul Geurink LUMC
Paul de Koning

Paul de Koning

Dr Paul de Koning (1958) has a MD and PhD (neuroscience) both from Utrecht University in the Netherlands. After some time in academia (training neurologist) he joined the pharmaceutical industry in 1988. He worked at Solvay Pharmaceuticals as Head of Clinical Pharmacology and Head of CNS Development. At Zeneca he served as the Global Head Clinical Immunology and at AstraZeneca as Global Head ECG centre and Clinical Pharmacology Units. His last Pharma position was with Astellas as Global Head Pain Therapeutic Area and Vice President (VP), Global Head of Clinical Pharmacology and Exploratory Development. In 2015 Paul resigned from Astellas to take a sabbatical. He decided to pursue his ambition to use his experience and expertise to teach on (exploratory) drug development and mentorcoach (young) scientists in the areas of leadership (leadership effectiveness and cross-cultural leadership) and personal development. In 2016 Paul established his own company, Paul de Koning Coaching and Consulting. He completed formal coach training as well as formal leadership courses at universities in EU (Nijenrode, Rotterdam School of Management and (INSEAD) as well as USA (Duke). Paul teaches on drug development at Utrecht University and the Oncode Institute.

Get In Touch:


Saman Honarnejad Pivot Park Screening Centre

Good governance

To ensure good governance, Oncode has developed its Good Governance Charter based on the rules in the Dutch Corporate Governance Code and the Good Governance Code for charities (SBF-Code Goed Bestuur).

The Good Governance Charter constitutes the regulations of Oncode’s most prominent and influential boards and committees, and also comprehends key policies. Please find the Good Governance Charter here. Please note that the Good Governance Charter is still work in progress and will be finalized soon.

Oncode Institute is a foundation. Please find Oncode’s articles of association here.

ANBI information

Please find Oncode on the ANBI website.